The \"CAR T-Cell Therapy for Multiple Myeloma - Market Insights and Market Forecast - 2030\" report has been added to ResearchAndMarkets.com's offering.<\/p>\n
This report delivers an in-depth understanding of the CAR T-Cell Therapy use for Multiple Myeloma as well as the CAR T-Cell Therapy market trends for Multiple Myeloma in the 6MM i.e., United States and EU5 (Germany, Spain, Italy, France and the United Kingdom).<\/p>\n
The Multiple Myeloma CAR T-Cell Therapy market report provides current treatment practices, emerging drugs, CAR T-Cell Therapy market share of the various CAR T-Cell Therapies for Multiple Myeloma, the individual therapies, current and forecasted Multiple Myeloma CAR T-Cell Therapy market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Multiple Myeloma treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.<\/p>\n
Reasons to Buy<\/p>\n
Report Highlights<\/p>\n
Key Topics Covered: <\/p>\n
1. Key Insights <\/p>\n
2. Executive Summary <\/p>\n
3. CAR T-Cell Therapy Market Overview at a Glance <\/p>\n
3.1 Market Share (%) Distribution of CAR T-Cell Therapy for MM in 2030<\/p>\n
4. CAR T-Cell Therapy Background and Overview <\/p>\n
4.1 Introduction<\/p>\n
4.1.1 CARs Generations<\/p>\n
4.1.2 Genetic Engineering of T-Cells<\/p>\n
4.1.3 How CAR T-Cell Therapy Works<\/p>\n
4.2 The promise of CAR T-cell targeting B cell maturation antigen (BCMA) in multiple myeloma<\/p>\n
4.3 Current challenges in CAR T<\/p>\n
4.3.1 Therapeutic side effects<\/p>\n
4.3.2 CAR T-cells lack of success<\/p>\n
4.4 CAR T-cell therapy: Route to reimbursement<\/p>\n
4.5 Unmet needs<\/p>\n
5. CAR T-Cell Therapy for Multiple Myeloma (MM): 6 Major Market Analysis <\/p>\n
5.1 Key Findings<\/p>\n
5.2 Market Size of CAR T-Cell Therapy in 6MM<\/p>\n
5.2.1 Market Size of CAR T-Cell Therapy by Therapies<\/p>\n
6. Market Outlook <\/p>\n
7. Emerging Drug Profiles for Multiple Myeloma <\/p>\n
7.1 bb2121: Celgene Corporation<\/p>\n
7.1.1 Product Description<\/p>\n
7.1.2 Research and Development<\/p>\n
7.1.3 Product Development Activities<\/p>\n
7.2 JNJ-68284528 (LCAR-B38M): Janssen Research & Development<\/p>\n
7.2.1 Product Description<\/p>\n
7.2.2 Research and Development<\/p>\n
7.2.3 Product Development Activities<\/p>\n
7.3 P-BCMA-101: Poseida Therapeutics<\/p>\n
7.3.1 Product Description:<\/p>\n
7.3.2 Research and Development<\/p>\n
7.3.3 Product Development Activities<\/p>\n
7.4 CAR-CD44v6: MolMed S.p.A.<\/p>\n
7.4.1 Product Description<\/p>\n
7.4.2 Research and Development<\/p>\n
7.4.3 Product Development Activities<\/p>\n
7.5 JCARH125 (Orvacabtagene autoleucel): Celgene Corporation<\/p>\n
7.5.1 Product Description<\/p>\n
7.5.2 Research and Development<\/p>\n
7.5.3 Product Development Activities<\/p>\n
7.6 Descartes-08: Cartesian Therapeutics<\/p>\n
7.6.1 Product Description<\/p>\n
7.6.2 Research and Development<\/p>\n
7.7 CT053 : CARsgen Therapeutics)<\/p>\n
7.7.1 Product Description<\/p>\n
7.7.2 Research and Development<\/p>\n
7.7.3 Product Development Activities<\/p>\n
Companies Mentioned <\/p>\n
For more information about this report visit https:\/\/www.researchandmarkets.com\/r\/auj3ij<\/a><\/p>\n View source version on businesswire.com: https:\/\/www.businesswire.com\/news\/home\/20200409005373\/en\/<\/a><\/p>\n Contacts<\/p>\n ResearchAndMarkets.comLaura Wood, Senior Press Managerpress@researchandmarkets.com<\/a> For E.S.T Office Hours Call 1-917-300-0470For U.S.\/CAN Toll Free Call 1-800-526-8630For GMT Office Hours Call +353-1-416-8900<\/p>\n <\/p>\n Read the original here: The \"CAR T-Cell Therapy for Multiple Myeloma - Market Insights and Market Forecast - 2030\" report has been added to ResearchAndMarkets.com's offering. Continue reading
\nCAR T-Cell Therapy for Multiple Myeloma - Global Market Insights and Market Forecast to 2030 - ResearchAndMarkets.com - Yahoo Finance<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"